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higher risk of relapse, lower quality of life and higher medical costs. The adherence 
measure, persistency, refers to the duration a patient continues with therapy. This 
study aims to evaluate the non-pharmacy medical costs associated with the persistency 
of DMT’s in patients with MS. METHODS: A decision-analytic model was designed 
using persistency rates, health care resource use and costs from the published litera-
ture. The model evaluated the medical costs associated with the persistence, switching, 
and discontinuation rates of patients on interferon β1a IM, interferon β1b SC, and 
interferon β1a SC over a 2-year time horizon. Using 6-month intervals in the model, 
patients could switch to a comparator treatment, discontinue treatment, or persist/
remain on their current treatment, and would incur the non-pharmacy medical costs 
associated with each. For patients who switched treatments, the model assumed an 
equal probability of switching to the three remaining DMTs. The model also assumed 
that patients who discontinued therapy would initiate on a different therapy after one 
month of discontinuing. The overall medical costs related to persisting on treatment, 
switching treatment or discontinuing treatment were calculated for all treatment arms. 
RESULTS: Based on the results from the model, an annual per-patient medical cost 
of $7423 was observed for interferon β1a IM patients, showing a medical cost advan-
tage over patients on interferon β1b SC ($8144; 8.9%), and interferon β1a SC ($7552; 
1.7%). CONCLUSIONS: MS is a lifelong disease that requires continuous treatment. 
The results of this model show that interferon β1a IM is a cost-saving treatment for 
the medical costs associated with MS patients on disease modifying therapies.
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OBJECTIVES: Cerebrospinal ﬂ uid (CSF) leak is an unavoidable consequence of 
cranial surgery with leak rates between 0% to 25% and resulting costs ranging from 
£9,000 to £36,000. The use of polyethylene glycol (PEG) hydrogel dural sealant as 
an adjunct to sutured closure has been shown to reduce CSF leak rates as compared 
with sutures alone in cranial procedures (GR Cosgrove et al, 2007). Our hypothetical 
analysis applied the potential cost offsets of using PEG hydrogel sealant as an adjunct 
to sutured closure in 200 cranial procedures assuming CSF leak rates of 4.5% (9/200) 
(GR Cosgrove et al, 2007), compared with 10% (20/200) for ﬁ brin sealant (JA Gro-
tenhuis, 2005). METHODS: The incremental additional cost for treating CSF leaks 
using total patient costs for those with CSF leaks (£25,253) compared to those without 
CSF leaks (£10,497) was estimated at £14,756 in a Dutch study (JA Grotenhuis, 
2005). We applied this CSF leak cost to estimate potential UK hospital cost offsets 
on 200 hypothetical cranial patients using PEG hydrogel sealant (£300/treatment), 
compared with ﬁ brin sealant (£133/treatment) on all 200 patients. RESULTS: Use of 
a PEG hydrogel sealant compared with ﬁ brin sealant could potentially save £137,611 
(or £688/patient) for a hospital that performed 200 cranial surgery procedures using 
a PEG hydrogel sealant compared with using ﬁ brin sealant on all 200 procedures. 
CONCLUSIONS: This study demonstrates the potential economic advantages of using 
a PEG hydrogel sealant in cranial procedures. Future clinical direct comparative 
studies would be beneﬁ cial to conﬁ rm these ﬁ ndings and understand the possible 
economic advantages for other types of dural surgeries.
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OBJECTIVES: Epilepsy is the second most frequent neurological disease among 
adults; approximately 50–60 thousand people suffer from epilepsy in Hungary. With 
our survey we aimed to assess the cost of illness from a societal viewpoint as well as 
the quality of life associated with epilepsy in Hungary. METHODS: We conducted a 
cross-sectional questionnaire survey of 100 consecutive patients in 2 epilepsy centres 
in Hungary in collaboration with epilepsy specialists. The self-developed questionnaire 
consisted of general and disease-speciﬁ c parts to determine costs associated with 
epilepsy. Questions related to basic demographic characteristics, disease progression 
and health and social services used in the past 12 months, disease-associated non-
medical services, as well as the productivity losses of epilepsy. Two generic quality of 
life questionnaires, EQ-5D and SF-36 were also used. RESULTS: A total number of 
100 patients were assessed (60% female). The average age was 36.7 years (SD. 12.5), 
average disease duration was 15 years (SD. 12). Quality of life calculations resulted 
in mean of 0.83 (SD. 0.24) in EQ-5D, 74 (SD. 16) in VAS scale and 72.3 (SD. 20.2) 
in SF-36. Cost-of-illness calculations were carried out and direct (15%) and indirect 
costs (85%) were determined. The annual total cost of epilepsy per capita was esti-
mated to be a mean of c5179 (SD. c10,822) with the human resource method, while 
c2,552/capita/year (SD. 8659) by the friction cost method. CONCLUSIONS: Compar-
ing the 100 patients’ data with data from previous EQ-5D based population-sample 
survey shows that quality of life among people with epilepsy was lower than among 
the average Hungarian population. We found signiﬁ cant correlation (at P < 0.05) 
among all of the quality of life results and the yearly total costs (calculating both with 
human capital and friction cost methods).
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OBJECTIVES: To estimate long-term disability costs associated with tuberous sclero-
sis complex, a rare multisystem genetic disease, in Brazil. METHODS: Literature 
review for TSC long-term disability and economic burden was performed (Pubmed, 
LILACS, SciELO, CRDs). Cost estimation was limited to epilepsy (most prevalent TSC 
disorder). Cost of lost productivity in patients since epilepsy onset in childhood and 
carried in adulthood as well as caregivers’ productivity costs were estimated. The 
Human Capital Method was adopted and potential lost working years estimated till 
an active age of 65 years. It was assumed a caregiver for all ages. Average income, 
unemployment rate due to epilepsy, productivity growth and epidemiology data were 
obtained from the literature and from the Brazilian Institute of Geography and Sta-
tistics. Mean annual productivity cost per patient, total productivity cost per patient 
and the total productivity burden of TSC-related epilepsy were calculated. Costs were 
estimated in 2008 Reals and discounted at 5%. Univariate sensitivity analysis was 
conducted for epidemiology data, employment status rate, productivity growth, dis-
count rate and time horizon. RESULTS: Productivity loss was 47, 30 and 65 years 
for epilepsy onset in childhood and adulthood and caregivers, respectively. The dis-
counted and not discounted mean annual productivity cost per patient were R$1,970 
and R$11,323, total productivity cost per patient R$97,882 and R$691,150 and total 
productivity burden of TSC-related epilepsy in Brazil R$1,568,965,961 and 
R$11,078,536,271, respectively (1Euro = 3.24Reals). Results were sensitive to all the 
parameters varied in the sensitivity analysis, especially discount rate. CONCLU-
SIONS: TSC-related epilepsy is a chronic disorder associated with loss of productivity 
with a signiﬁ cant economic burden in Brazil. Although signiﬁ cant, the economic 
burden related to productivity loss is expected to be even higher since there are still 
costs deriving from absenteeism of patients and caregivers when employed looking for 
health services to be included in further analysis.
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OBJECTIVES: To determine the costs and medical resource use for the management 
of injection-site reactions (ISRs) and ﬂ u-like symptoms (FLS) associated with injectable 
disease-modifying drugs (DMDs) used to treat patients with relapsing–remitting mul-
tiple sclerosis (RRMS) in the UK. METHODS: A survey was carried out amongst 
NHS nurses to understand the management of adverse events occurring with injectable 
DMD use. Data were collected via a postal questionnaire. Responses were compiled 
for the frequency and duration of side-effects, support received and medical consulta-
tions required for adverse event management. The unit costs were derived from the 
Personal Social Services Research Unit, the Ofﬁ ce for National Statistics and the British 
National Formulary. Once all parameters and unit prices were characterised with 
conservative approaches for missing data (e.g. no GP consultation mandatory before 
antibiotics prescription), computations were processed to determine means and stan-
dard deviations (SDs). RESULTS: In total, 19 NHS nurses managing signiﬁ cant 
numbers of patients with MS for different primary care trusts participated in the 
costing survey. On average, the nurses reported that patients experienced 27 ISRs per 
year of those 33% experienced ISRs only at treatment start while 21% experienced 
ISRs continuously during the year. Seventy-four percent experienced FLS only at 
treatment start and 11% continuously. The average cost for the management of ISRs 
per year was £187 (SD £209) equivalent to an average cost of £7 per event. The 
average cost for the management of FLS per year was £166 (SD £144) equivalent to 
an average cost of £6 per event. CONCLUSIONS: This is the ﬁ rst UK study to provide 
data on the costs associated with management of ISRs and FLS occurring with inject-
able DMDs. These data, alongside prevalence estimates, enabled us to calculate the 
costs of managing adverse events associated within DMDs in an economic model.
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OBJECTIVES: Huntington’s disease (HD) is a rare neurodegenerative disease leading 
to sustained disability and poor health-related quality of life (HRQOL). As new treat-
ments are in development for HD, data on the burden of disease are required. This 
study evaluated patient health status, patient and caregiver HRQoL and costs in HD. 
METHODS: Euro-HDB is a European cross-sectional survey being conducted in eight 
European countries. Self-reported questionnaires were completed by patients and care-
givers. The patient questionnaire includes the Huntington Self-Assessment Instrument, 
a speciﬁ c tool that assesses clinical characteristics, HRQoL and health care resource 
utilization. The EQ5D questionnaire and the SF36 Survey are also included. RESULTS: 
To date, 201 patients have been enrolled in France and 124 in Italy. 
All levels of disease severity are represented. Average annual costs from societal 
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perspective are c5,325 (±9588), c18,045c (±34487) and c41,716 (±35211) at mild, 
moderate and severe stages respectively in France; c3,125 (±4319), c8,457 (±18374) 
and c5,069 (±11747) in Italy. Associated EQ-5D utilities are respectively 0.79 (±0.18), 
0.39 (±0.37), −0.11 (±0.3) in France; 0.59 (±0.44), 0.39 (±0.42), 0.25 (±0.44) in Italy. 
The primary cost driver is productivity loss. In France, hospitalization and nursing 
home costs are the main components of direct costs. For more severely affected patients, 
medical resource utilization diminishes while caregiver involvement increases signiﬁ -
cantly (the shift is greater in Italy than France). Physical, mental and social HRQoL 
domains are all seriously affected. CONCLUSIONS: Euro-HDB is the ﬁ rst study to 
comprehensively assess the cost and HRQOL burden of HD. The 1:5 cost ratio 
(Italy : France) is consistent across most of the cost items, suggesting that differences in 
health care systems, access to health care and cultural attitudes towards caring for 
patients at home have a large impact on a country’s overall costs. Results suggest that 
HD has greater impact on HRQOL than Parkinson’s disease and Alzheimer’s disease.
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The economic burden of Multiple Sclerosis (MS) on society and the individuals con-
cerned is not known. Documenting such costs is essential for several reasons: costs of 
illness is a key factor of optimal disease management policies, knowledge of cost is 
useful for allocating research and development. The aim of our study as the ﬁ rst 
pharmacoeconomic investigation in Iran was to estimate the costs of multiple sclerosis 
according to severity of disease. Total, direct and indirect costs were compared in 160 
patients divided into three groups categorized by disease severity: stage I Expanded 
Disability Status Scale (EDSS < 2.5), stage II (EDSS 3–4.5) and stage III (EDSS > 5). 
The majority of these patients (94%) developed relapsing- remitting MS. a minority 
of the patients (0.2–4%) developed secondary progressive and primary progressive 
MS. Cost evaluation was performed from the societal perspective and covered the 
one-year period. The study was carried out at the Division of Neurology at Ghaem 
Hospital and MS association in Mashhad in northeast of Iran and was approved by 
the local ethics committee. The mean total cost/patient for one year was estimated at 
$27,095, $27,997and $31,662 for stage I, II and III, respectively. Both direct and 
indirect costs increased with MS progression. For indirect cost the main item was 
productivity loss. The mean extra medicine (treatments for MS symptoms and adverse 
effects of medications) cost/patient for one year was calculated at $19,036. This study 
conﬁ rms that MS represents a high economic burden to patients and society, with 
direct costs greatly exceeding indirect costs. As costs increase with disease progression, 
treatment efforts should focus on patients in the early stages of MS. Disease support 
system that monitors a variety of common progressive signs for the MS individuals is 
a key element of a management program as well.
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OBJECTIVES: According to EU-guidelines testing all patients on interferon-beta 
(IFNb) for presence of neutralizing antibodies (NAB) is recommended irrespective of 
clinical course and stop IFNb or switch to alternatives in patients who developed 
persistent NAB; based on the fact that development in persistently NAB-positive 
patients equals that of placebo-treated patients. Economic impact of NAB-testing in 
MS-patients has not been explored yet. METHODS: This analysis estimated the 
economic impact of NAB-testing versus not testing during IFNb treatment in MS-
patients (n = 3590) on Austria’s health care system. a cost of illness model (decision 
tree combined with an integrated Markov model, time horizon 5 years), based on the 
cohort of IFNb-treated patients was performed. Two alternatives were compared: 
Cost-effectiveness of NAB-testing versus no NAB-testing. The NAB-testing arm 
allowed switching to alternative therapies whereas no-NAB-testing did not. Direct 
costs comprised all treatment-costs of symptoms due to MS. Indirect costs were not 
included. All costs represent data from 2010 (discounted at 5%p.a). Clinical data and 
resource use were determined by literature/experts. Efﬁ cacy assessment was based on 
the outcome measure “relapses avoided.” RESULTS: Total discounted costs for all 
Austrian MS-patients on IFNb-therapy (incl. testing) from a health care system’s 
perspective amount to c187,764,180 for 5 years. Total costs for all MS-patients 
without testing amount to c176,331,610. The difference of costs between tested 
patients, and therefore switching, and not tested patients values c11,432,570. Con-
sidering all IFNb-treated patients and a time horizon of 5 years 1400 relapses can be 
avoided. Testing for NAB leads to costs per relapse avoided of c24,383p.a. versus 
c27,569p.a. when no tests are done resulting in a difference of c3,186 per patient in 
favour of NAB-testing. CONCLUSIONS: General NAB-testing in MS-patients on 
IFNb-therapy is reasonable and cost-effective. Patients switching to effective and more 
expensive alternatives do not account for higher health care costs. Furthermore, less 
relapses increase QoL.
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OBJECTIVES: Restless legs syndrome (RLS) affects 2 to 15% of the US population. 
Limited data exist on patient characteristics and charges associated with emergency 
department (ED) visits among patients with RLS. METHODS: Data from the 2007 
Healthcare Cost and Utilization Project’s Nationwide Emergency Department Sample 
were used. Patients were selected for inclusion if they had a diagnosis of RLS (ICD-
9-CM code 333.94). Study measures included patient demographics and charges 
associated with the ED visit. Study measures were reported separately for patients 
with a primary versus secondary RLS diagnosis. Among patients with a secondary 
RLS diagnosis, the most common primary diagnoses were reported. RESULTS: A total 
of 6133 patients with a primary RLS diagnosis and 140,931 patients with a secondary 
RLS diagnosis were identiﬁ ed. Common primary diagnoses among patients with a 
secondary RLS diagnosis included respiratory symptoms (7.0%), general symptoms 
(4.6%), and pneumonia (3.7%). Mean (Std. Err.) age was 54.5 (0.6) years among 
patients with a primary diagnosis and 64.0 (0.3) years among patients with a second-
ary diagnosis. In both cohorts, over two-thirds of patients were female, the most 
common geographic regions were the South and Midwest, and Medicare was the most 
common primary payer (41.0% of patients with a primary diagnosis and 59.3% of 
patients with a secondary diagnosis). Over 90% of patients with a primary diagnosis 
had a routine discharge compared to only 26.6% of patients with a secondary diag-
nosis, and most patients with a secondary diagnosis were admitted to the facility as 
an inpatient. Mean (Std. Err.) charges were $816 ($48) for patients with a primary 
diagnosis and $2,043 ($62) for patients with a secondary diagnosis. CONCLUSIONS: 
This nationally representative study suggests that patients admitted to the ED with 
RLS accrue substantial costs during their visit. Further research is needed to more fully 
assess the total economic burden of the disease.
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OBJECTIVES: A reimbursement policy issued by the Federal Joint Committee in 
Germany to reassess the beneﬁ t of cholinesterase inhibitors every six months in order 
to receive continued coverage by the Statutory Health Insurance triggered an addi-
tional need to periodically assess the cost-beneﬁ t of galantamine in the treatment of 
mild-to-moderate Alzheimer’s disease (AD). An economic model speciﬁ cally designed 
for the purposes of such an assessment was developed using the most up-to-date 
IQWiG guidelines for cost-beneﬁ t assessment. METHODS: The model uses a discrete 
event simulation to predict the course of AD through changes in cognition, behavioral 
disturbance, and function over time, and compare the costs and beneﬁ ts of galan-
tamine versus no-drug treatment and ginkgo biloba. Clinical data were mainly derived 
from analyses of pooled data from clinical trials. Epidemiological and cost data were 
obtained from literature and public data sources. Costs (2009 c) from the perspective 
of the German Statutory Health Insurance were used. Both costs and beneﬁ ts were 
discounted at 5%. Sensitivity analyses were performed to assess the robustness of the 
model outcomes. RESULTS: Over a 10-year period, galantamine on average delays 
time to severe stage of the disease by 3.57 and 3.36 months, compared to no-drug 
treatment and ginkgo biloba, respectively. Galantamine also reduces time spent insti-
tutionalized by 2.34 and 2.21 months, compared to no-drug treatment and ginkgo 
biloba, respectively. The use of galantamine is projected to yield net savings of c3,978 
and c3,972 per patient compared to respective treatments. CONCLUSIONS: Our 
analyses suggest that compared to no-drug treatment and ginkgo biloba, treatment 
with galantamine not only improves clinical beneﬁ ts, but also achieves savings in 
health care costs associated with care for patients with mild-to-moderate AD in 
Germany.
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OBJECTIVES: To evaluate in the French setting the cost-effectiveness of memantine 
as adjunct therapy to Cholinesterase inhibitors (ChEI) compared to ChEI monother-
apy in Alzheimer’s disease (AD) patients. METHODS: A cost-effectiveness analysis 
employed a 3-state Markov model (“non-institutionalized,” “institutionalized” and 
“dead”) and compared the treatment alternatives in terms of time to nursing home 
admission, Quality Adjusted Life-years (QALYs), and costs over a 7-year time horizon. 
Annual transition probabilities between states were derived from two observational 
cohort studies: Lopez et al 2009 (US) for institutionalization probabilities and Helmer 
et al 2001 (FR) for death probabilities. Costs were valued from health care system 
and societal perspectives, and included cost of AD medications (French National 
